Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. (Q38393922)

From Wikidata

Jump to navigation Jump to search

scientific article published on 06 April 2016

Language	Label	Description	Also known as
English	Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.	scientific article published on 06 April 2016

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jose A Garcia-Saenz

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

M Martin

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

P Fumoleau

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

J A Dewar

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

J Albanell

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

S A Limentani

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

M Campone

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

J C Chang

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

M Patre

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

A Strasak

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

S L de Haas

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

J Xu

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

publication date

6 April 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1249-1256

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW157

21 January 2018

Identifiers

10.1093/ANNONC/MDW157

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052654%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38393922&oldid=1672289950"